Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 3,221 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: DNA Clear all

Conditions: Brain Cancer
Interventions: Nivolumab, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Ibrutinib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 5 more

Conditions: Chronic Hepatitis B
Interventions: telbivudine, adefovir dipivoxil; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: Atlanta, Georgia • Flushing, New York • Sterling, Virginia

Conditions: Primary Central Nervous System Lymphoma (PCNSL)
Interventions: Nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cytomegalovirus Infections
Interventions: CMV Specific T Cell donor lymphocyte infusion; Biological
Lead sponsor: Nelson Chao; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sarcoma
Interventions: valproic acid; Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 4 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 60 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Genital Herpes
Interventions: AG-707; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Indianapolis, Indiana • Portland, Oregon • Seattle, Washington

Conditions: Keratitis, Herpetic, Ocular Herpes Simplex, Herpes Simplex
Interventions: Stress, Acyclovir; Behavioral · Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 8
States / cities: San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: sargramostim; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 5 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Interventions: Letermovir; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 249 Days to 305 Days
Enrollment: 1,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 39
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kaposi's Sarcoma, Herpesviridae Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer
Interventions: Fludarabine, Cyclophosphamide, Young TIL, Aldesleukin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
Interventions: prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study; Diagnostic Test
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Engerix B, Twinrix for ATN 024, Recombivax, Twinrix for ATN 025; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 25 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Cidofovir, Probenecid; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Solid Tumors, Identified by NGS, PCR or IHC
Interventions: Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 5
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 2 more

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 25
States / cities: Duarte, California • Los Angeles, California • Orange, California + 20 more

Search by objective public record fields.

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT

Valproic Acid in Treating Patients With Kaposi's Sarcoma

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

Herpetic Eye Disease Study (HEDS) II

High-Risk HPV Infections in Women Aged 25 to 65

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis

Immunologic Memory (Supp. of ATN 024)

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders